Do analysts rate BPTH or CERO?

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation & earnings, BPTH or CERO?

Bio-Path is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A CERo Therapeutics N/A N/A -$8.30M -$71.01 N/A

Is BPTH or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% CERo Therapeutics N/A N/A -209.40%

Do analysts recommend CERO or VIVS?

CERo Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CERO or CANF more profitable?

Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Can-Fite BioPharma N/A N/A N/A

Do analysts rate CMND or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Clearmind Medicine. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings & valuation, CMND or CERO?

Clearmind Medicine is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A CERo Therapeutics N/A N/A -$8.30M -$71.01 N/A

Is CMND or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics (CERO) Competitors

$0.01 0.00 (0.00%)

As of 07/24/2026 03:59 PM Eastern

Compare

CERO vs. FLGC, BPTH, VIVS, CANF, and CMND

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include Flora Growth (FLGC), Bio-Path (BPTH), VivoSim Labs (VIVS), Can-Fite BioPharma (CANF), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry.

How does CERo Therapeutics compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Flora Growth's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Flora Growth	Neutral
CERo Therapeutics	Neutral

CERo Therapeutics has lower revenue, but higher earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Flora Growth currently has a consensus target price of $30.00, suggesting a potential upside of 1,968.97%. CERo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 299,900.00%. Given CERo Therapeutics' higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Flora Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. CERo Therapeutics' return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
CERo Therapeutics	N/A	N/A	-209.40%

Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market.

Summary

Flora Growth beats CERo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CERo Therapeutics compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Bio-Path is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

CERo Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
CERo Therapeutics	N/A	N/A	-209.40%

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Bio-Path had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for CERo Therapeutics. Bio-Path's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
CERo Therapeutics	Neutral

Bio-Path has a beta of -0.51, meaning that its stock price is 151% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

CERo Therapeutics beats Bio-Path on 8 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to VivoSim Labs?

CERo Therapeutics (NASDAQ:CERO) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 2.5% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CERo Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. CERo Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

CERo Therapeutics has higher earnings, but lower revenue than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
VivoSim Labs	$131K	11.17	-$13.84M	-$5.36	N/A

CERo Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CERo Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, VivoSim Labs had 5 more articles in the media than CERo Therapeutics. MarketBeat recorded 5 mentions for VivoSim Labs and 0 mentions for CERo Therapeutics. VivoSim Labs' average media sentiment score of 1.12 beat CERo Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
VivoSim Labs	Positive

Summary

CERo Therapeutics and VivoSim Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to Can-Fite BioPharma?

CERo Therapeutics (NASDAQ:CERO) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

CERo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 299,900.00%. Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,279.31%. Given CERo Therapeutics' higher probable upside, research analysts plainly believe CERo Therapeutics is more favorable than Can-Fite BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

CERo Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Can-Fite BioPharma	N/A	N/A	N/A

Can-Fite BioPharma has higher revenue and earnings than CERo Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Can-Fite BioPharma	$405K	5.16	-$7.63M	-$22.80	N/A

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Can-Fite BioPharma	Neutral

Summary

Can-Fite BioPharma beats CERo Therapeutics on 8 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Clearmind Medicine had 4 more articles in the media than CERo Therapeutics. MarketBeat recorded 4 mentions for Clearmind Medicine and 0 mentions for CERo Therapeutics. Clearmind Medicine's average media sentiment score of 0.83 beat CERo Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Clearmind Medicine	Positive
CERo Therapeutics	Neutral

Clearmind Medicine has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 299,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Clearmind Medicine is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

CERo Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
CERo Therapeutics	N/A	N/A	-209.40%

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Clearmind Medicine and CERo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$451K	$3.07B	$6.91B	$12.20B
Dividend Yield	N/A	2.07%	2.67%	9.80%
P/E Ratio	0.00	20.29	27.14	23.63
Price / Sales	N/A	339.70	521.03	88.64
Price / Cash	N/A	26.63	26.39	46.67
Price / Book	0.00	4.13	10.25	6.08
Net Income	-$8.30M	$65.94M	$3.60B	$331.70M
7 Day Performance	N/A	-2.41%	-0.30%	-0.05%
1 Month Performance	N/A	-5.87%	-1.78%	-2.63%
1 Year Performance	N/A	9.76%	18.20%	13.91%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	N/A	$0.01 flat	$30.00 +299,900.0%	-99.9%	$451K	N/A	N/A	8	Gap Up High Trading Volume
FLGC Flora Growth	N/A	$2.18 -2.7%	$30.00 +1,276.1%	-94.0%	$2.28M	$57.61M	N/A	280	Positive News Gap Up
BPTH Bio-Path	N/A	$0.04 +22.0%	N/A	-72.6%	$2.15M	N/A	N/A	10	Gap Up
VIVS VivoSim Labs	0.9414 of 5 stars	$0.83 +3.2%	N/A	-81.2%	$2.11M	$142K	N/A	20	Short Interest Decrease
CANF Can-Fite BioPharma	1.8593 of 5 stars	$3.22 -1.2%	$44.00 +1,266.5%	-83.7%	$2.11M	$405K	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. FLGC, BPTH, VIVS, CANF, and CMND

How does CERo Therapeutics compare to Flora Growth?

Summary

How does CERo Therapeutics compare to Bio-Path?

Summary

How does CERo Therapeutics compare to VivoSim Labs?

Summary

How does CERo Therapeutics compare to Can-Fite BioPharma?

Summary

How does CERo Therapeutics compare to Clearmind Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. FLGC, BPTH, VIVS, CANF, and CMND

How does CERo Therapeutics compare to Flora Growth?

Does the media refer more to FLGC or CERO?

Which has preferable earnings & valuation, FLGC or CERO?

Do insiders & institutionals hold more shares of FLGC or CERO?

Do analysts rate FLGC or CERO?

Is FLGC or CERO more profitable?

Which has more risk and volatility, FLGC or CERO?

Summary

How does CERo Therapeutics compare to Bio-Path?

Which has stronger valuation & earnings, BPTH or CERO?

Is BPTH or CERO more profitable?

Do institutionals and insiders hold more shares of BPTH or CERO?

Does the media prefer BPTH or CERO?

Which has more volatility and risk, BPTH or CERO?

Do analysts rate BPTH or CERO?

Summary

How does CERo Therapeutics compare to VivoSim Labs?

Do institutionals & insiders hold more shares of CERO or VIVS?

Is CERO or VIVS more profitable?

Which has higher valuation & earnings, CERO or VIVS?

Do analysts recommend CERO or VIVS?

Which has more volatility and risk, CERO or VIVS?

Does the media prefer CERO or VIVS?

Summary

How does CERo Therapeutics compare to Can-Fite BioPharma?

Do analysts rate CERO or CANF?

Which has more risk and volatility, CERO or CANF?

Is CERO or CANF more profitable?

Which has stronger earnings & valuation, CERO or CANF?

Do insiders & institutionals believe in CERO or CANF?

Does the media favor CERO or CANF?

Summary

How does CERo Therapeutics compare to Clearmind Medicine?

Does the media favor CMND or CERO?

Which has more risk and volatility, CMND or CERO?

Do analysts rate CMND or CERO?

Which has preferable earnings & valuation, CMND or CERO?

Is CMND or CERO more profitable?

Do insiders & institutionals have more ownership in CMND or CERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools